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Abstract
Although Artemisia iwayomogi (AI) has been shown to improve the lipid metabolism, its mode of action is poorly
understood. In this study, a 95% ethanol extract of AI (95EEAI) was identified as a potent ligand of peroxisome proliferator-
activated receptord (PPARd) using ligand binding analysis and cell-based reporter assay. In cultured primary human skeletal
muscle cells, treatment of 95EEAI increased expression of two important PPARd-regulated genes, carnitine palmitoyl-
transferase-1 (CPT1) and pyruvate dehydrogenase kinase isozyme 4 (PDK4), and several genes acting in lipid efflux and
energy expenditure. Furthermore, 95EEAI stimulated fatty acid oxidation in a PPARd-dependent manner. High-fat diet-
induced obese mice model further indicated that administration of 95EEAI attenuated diet-induced obesity through the
activation of fatty acid oxidation in skeletal muscle. These results suggest that a 95% ethanol extract of AI may have a role as
a new functional food material for the prevention and/or treatment of hyperlipidermia and obesity.
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Introduction
Skeletal muscle is an important organ in the whole body
regulation of energy homeostasis and the main site of fatty acid and
glucose oxidation [1,2]. PPARd plays a critical role in skeletal
muscle metabolism via transcriptional regulation of downstream
gene expression [3]. The reported in vivo effects of PPARd activation
include improvement of dylipidemia and hyperglycemia, preven-
tion of diet-induced obesity, enhancement of insulin sensitivity and
modulation of muscle fiber type switching as demonstrated by
systemic ligand administration or by generation of transgenic mice
that over-express an active PPARd [4–7]. Most of the observed
beneficial effects arebelieved to be mediated by increasing fatty acid
catabolism and mitochondrial function in muscle and adipocytes
[8]. Thus, it is proposed that activators of PPARd may have
therapeutic utility in the treatment of metabolic disease [9].
Artemisia herbs, a member of the Compositae, have long been used
in foods and in traditional medicine for treatment of diseases,
including diabetes and hepatitis [10]. Artemisia herbs have been
reported to have anti-diabetic and anti-hyperlipidemic activities in
diabetic patients and rats [11,12]. However, molecular mecha-
nisms whereby Artemisia exerts its benefit on lipid and glucose
metabolism remain unknown.
In this study, we screened medicinal herbs to search for natural
PPARd ligands. We found that a 95% ethanol extract of Artemisia
iwayomogi (95EEAI) directly interacted with PPARd, enhanced the
expression of genes involved in lipid catabolism and induced
PPARd-dependent activation of fatty acid oxidation. Furthermore,
administration of 95EEAI to mice fed a high-fat diet enhanced
fatty acid oxidation in the skeletal muscle and protected against
diet-induced obesity.
Materials and Methods
Ethics statement
A l la n i m a le x p e r i m e n t sw e r ea p p r o v e db yt h eA m o r e P a c i f i c
Institutional Animal Care and Use Committee and adhere to the
OECD guidelines. Permit numbers: AP11-101-FR012. No specific
permits were required for the described field studies. No specific
permissions were required for these locations/activities. We confirmed
that the location was not privately-owned or protected in any way and
the field studies did not involve endangered or protected species.
Preparation of an ethanol extract of Artemisia Iwayomogi
Three hundred grams of the aerial parts of Artemisia iwayomogi
was heated to 80uC with 70% ethanol for 3 h. The extract was
then filtered through Whatman No. 1 (Whatman, Piscataway, NJ,
USA) and loaded on a D-101 macroporous resin column, followed
by elution of the column with water (WEAI), 50% ethanol
(50EEAI) and 95% ethanol eluate (95EEAI) were obtained. After
evaporation, the solutions were freeze-dried.
PPARd coactivator assay
PPARd coactivator assay was performed using Lanthascreen
TM
time-resolved fluorescence resonance energy transfer (TR-FRET)
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manufacturer (Invitrogen, Carlsbad, CA, USA). All assays were
validated for their robustness by determining the respective Z9-factors
[13]. Measurements were performed on a VICTOR3_V Multilabel
Counter (WALLAC 1420; PerkinElmer Life and Analytical Sciences,
Rodgau, Germany) with instrument settings as described in the
manufacturer’s instructions for LanthaScreen
TM assays.
Luciferase Reporter Assay
PPARd-responsive luciferase reporter assay was performed
using Human Peroxisome Proliferator-Activated Receptor Delta
Reporter Assay System (Indigo Biosciences, PA, USA). PPARd
reporter cells (provided with assay system) are non-human
mammalian cells stably transfected with human PPARd and
PPARd-responsive luciferase reporter genes. Mock reporter cells
which contain only the PPARd-responsive luciferase vector were
also purchased from Indigo Biosciences. PPARd reporter cells and
mock reporter cells were cultured in Cell Recovery Medium 1
(CRM-1) for 4 h. The cells were treated with indicated
concentration of AI extracts for 24 h. Luciferase activity was
measured using luciferase detection reagent (Indigo Biosciences,
PA, USA) and Tecan infinite M200 Pro (Tecan, Grodig, Austria),
following the manufacturer’s recommended procedures. The
protein concentration of the cell lysate was determined using the
BCA protein assay kit (Pierce, Rockford, Illinois, USA). Luciferase
activity was normalized to the protein concentration of each
sample. The fold induction of normalized luciferase activity was
calculated relative to DMSO (vehicle)-treated cells, and represents
the mean of three independent samples per treatment group.
Human Primary Skeletal Muscle Cell Culture
Normal human skeletal muscle myoblasts were purchased from
LONZA (Walkersville, MD, USA) and cultured in skeletal muscle
growth medium (SkBM-2, SkGM-2 SingleQuots, LONZA Walk-
ersville, Inc., MD, USA), 100 units/ml penicillin, and 100 mg/ml
streptomycin in a humidified atmosphere of 5% CO2.T o
differentiate human myoblasts into myotubes, cells with a density
of 60–70% were grown in Dulbecco’s minimum essential medium:
Nutrient Mixture F-12 (DMEM/F-12) with 2% horse serum for 5
days. Myotubes were treated with PPARd agonist (GW501516,
Alexis Biochemicals, Lausen, Switzerland), various concentration
of AI extracts (WEAI, 50EEAI, 95EEAI) or the vehicle (DMSO)
for 24 h.
Small Interfering RNA Treatment
The PPARd small interfering RNA (siRNA) pool (a mixture of
three siRNAs for PPARd, cat. no. sc-36305) and control siRNA
(cat. no. sc-37007) were purchased from Santa Cruz Biotechnol-
ogy (Santa Cruz, CA, USA). For the transfection procedure, cells
were grown to 70% confluence, and PPARd and control siRNAs
were transfected using the Lipofectamine 2000 reagent (Invitro-
gen, Carlsbad, CA, USA) according to the manufacturer’s
instructions. Briefly, Lipofectamine 2000 reagent was incubated
with serum-free medium for 10 min. Subsequently, a mixture of
the respective siRNAs was added. After incubation for 15 min at
room temperature, mixture was diluted with medium and added
to each well. The final concentration of PPARd siRNA in each
well was 100 nM. After culturing for 48 h, cells were washed and
treated with GW501516 or AI extracts for an additional 24 h.
Real Time Quantitative RT-PCR
Total RNA was extracted with TRIzol (Gibco-BRL, Invitrogen
Corp., Carlsbad, CA, U.S.A.) according to the manufacturer’s
instructions. The pre-designed primers and probe sets of PPARd,
CPT1b, PDK4, uncoupling protein-3 (UCP3), PPARc coactivator 1a
(PGC1a), acyl-Coenzyme A dehydrogenase, long-chain (LCAD), and
glyceraldehyde-3-phosphate dehydrogenase (GAPDH) were obtained
from Applied Biosystems (assay ID for human: Hs00987011_m1,
Hs00993896_g1, Hs01037712_m1, Hs01106052_m1, Hs01016719_
m1, Hs01085277_m1, and Hs03929097_g1, respectively/ assay ID for
mouse: Mm01308156_g1 (CPT1b), Mm01166879_m1 (PDK4), Mm
00627598_m1 (UCP2), Mm00494077_m1 (UCP3), Mm01208835_
m1 (PGC1a), Mm00599660_m1 (LCAD), Mm99999915_g1 (GAP
DH)). The reaction mixture was prepared using a Quantitect probe
PCR kit (Qiagen, GmbH, Germany) according to the manufacturer’s
instructions. Reaction and analysis were performed using the Rotor-
Gene 3000 system (Corbett Research, Sydney, Australia). All reactions
were done in triplicate. The amount of mRNA was calculated by the
comparative CT method.
Western blot analysis
Myotubes were lysed in RIPA buffer (PBS, pH 7.4, containing
1% NP-40, 0.5% sodium deoxycholate, 0.1% SDS, and a protease
inhibitor cocktail). Forty micrograms of proteins were resolved on
10% NuPAGE gels run in an MES buffer system (Invitrogen,
Carlsbad, CA) and transferred to nitrocellulose membranes
according to the manufacturer’s protocol. Immunoreactive
proteins were revealed by enhanced chemiluminescence with
ECL Plus(Amersham, GE healthcare, Buckinghamshire, UK).
Antibodies against PPARd and GAPDH were purchased from
Santa Cruz Biotechnology. Blots were analyzed with a LAS-3000
imaging system (Fujifilm, Japan).
Fatty Acid Oxidation
Myotubes placed in a 12-well plate, or 400 mg of intact mouse
quadriceps muscles were washed and incubated in low glucose
DMEM (Invitrogen) containing 2% (w/v) fatty acid-free BSA,
Figure 1. Ligand-induced binding of a coactivator derived
peptide to PPARd in vitro. Interaction of fluorescein-labeled
coactivator peptide C33 and recombinant GST-PPARd bound by a
terbium-labeled anti-GST antibody was determined by TR-FRET.
GW501516, WEAI, 50EEAI and 95EEAI were used at the concentrations
indicated. Results are expressed as the ratio of fluorescence intensity at
520 nm (fluorescein emission excited by terbium emission) and 495 nm
(terbium emission). All data points represent averages of triplicates
(6S.D.).
doi:10.1371/journal.pone.0033815.g001
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3H]palmitic acid (3 mCi/well, Perki-
nElmer Life, Boston, MA, USA). After incubation, medium was
precipitated with an equal volume of 10% trichloroacetic acid
(Sigma) by centrifugation at 12,000 rpm for 10 min.. The
supernatant was extracted twice with chloroform/methanol (2:1)
and then counted for
3H2O production.
Glucose Uptake
Differentiated primary human muscle myotubes were incubated
in serum-free, low-glucose DMEM containing 0.1% BSA for 16 h
at 37uC. Cells were treated with GW501516, AI extracts and
vehicle for 24 h at 37uC and then stimulated with or without
100 nM insulin for 1 h at 37uC. Glucose uptake was initiated by
the addition of 2-deoxy-D-[
14C]glucose (PerkinElmer Life) at a
final concentration of 3 mmol/l for 10 min in HEPES buffer-saline
(140 mM NaCl, 5 mM KCl, 2.5 mM MgCl2, 1 mM CaCl2,
20 mM HEPES, pH 7.4). The reaction was terminated by
separating cells from the HEPES buffer saline and 2-deoxy-D-
[
14C]glucose. After three washes in ice-cold PBS, the cells were
extracted with 0.1% SDS and subjected to scintillation counting
for
14C radioactivity. The protein concentration was determined
with a BCA assay kit (Pierce, Rockford, IL, USA), and the
radioactivities were normalized by determining each total protein
concentration.
Animal Experiments
C57BL/6J mice (male, 5 weeks of age) were purchased from
Samtako (Osan, Korea). The mice were housed individually in a
temperature- and humidity-controlled (26.5uC and 35%) facility
with a 12-h light/dark cycle. All animals were allowed free access
to water and diets. After acclimatization for 1 week, mice were fed
a normal chow diet (D12450B, Research Diets, New Brunswick,
NJ, USA) or a high-fat diet (60% kcal fat, D12492, Research
Diets). Food consumption and body weight were recorded every
week. A 95EEAI was given at 200 mg/kg of body weight by oral
zoned needle once daily for 8 weeks. At the end of the experiment,
blood and quadriceps muscle tissue samples were collected from
the mice. Plasma triacylglycerol, total cholesterol and total ketone
bodies were measured by an automated TBA-120FR biochemical
analyzer (Toshiba) by using commercial assay kits (Dai-ichi Pure
Chemicals, Tokyo, Japan). Plasma-free fatty acids and blood
glucose levels were determined by a NEFA C-test (catalog no. 279-
75401, Wako Pure Chemical, Osaka, Japan) and GLU neo SINO-
Test (SINO-Test, Tokyo, Japan), respectively. Serum level of b-
hydroxybutyrate was measured with high sensitivity and specificity
according to the manufacturer’s directions (Autokit 3 b-hydroxy-
butyrate, Wako Diagnostics, Richmond, VA) by calculating the
rate of Thio-NADH (b-thionicotinamide adenine dinucleotide)
production spectrophotometrically at 405 nm upon oxidation of 3-
b-hydroxybutyrate.
Statistical Analysis
Experiments were performed at least three times. The data were
reported as a mean 6 S.D. Results were analyzed by Student’s t-
test or ANOVA using the program SPSS 11.0 (SPSS, Chicago, IL,
USA). Statistical significance was set at p#0.05.
Results
A 95EEAI is PPARd ligand
We found that a 95EEAI interacted with the PPAR d ligand
binding domain (LBD) (EC50=7 ug/ml, Z9-Factor=0.65,
Figure 1) in repeated assay. We then determined the ability of a
95EEAI to activate PPARd using cell-based PPARd-responsive
luciferase reporter assays. The synthetic PPARd agonist
GW501516 (1 mM) caused a strong luciferase activity (Figure 2A).
Similarly, a 95EEAI induced the luciferase activity in a dose-
dependent manner (Figure 2B), while WEAI and 50EEAI had no
effect (Figure 2A). Altogether, these results show that a 95EEAI is
capable of activating PPARd via interaction with LBD of PPARd.
Figure 2. Effects of 95EEAI on the transcriptional activity of
PPARd reporter cells. (A) Mock reporter cells (luciferase vector only)
and the PPARd reporter cells (PPARd expression vector+PPARd-
responsive luciferase reporter vector) were cultured, treated with
DMSO, GW501516 (1 mM), WEAI (100 mg/ml), 50EEAI (100 mg/ml) and
95EEAI (100 mg/ml) for 24 h before harvesting. (B) The effects of various
ranges of 95EEAI concentrations were analyzed. Values represent
averages of six independent experiments (6 S.D.). ***, p,0.005;
**, p,0.01 compared to vehicle control.
doi:10.1371/journal.pone.0033815.g002
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in a PPARd-dependent manner
We next examined whether a 95EEAI could induce PPARd-
regulated genes in human skeletal muscle cells (Figure S1). To
ensure that effects are PPARd-dependent, we also determined the
effect of 95EEAI on the expression of PPARd target genes in
muscle cells in which endogenous PPARd expression was knocked
down with RNAi. As shown in Figure 3A, mRNA expression of
PPARd was reduced by treatment with RNAi. A 95EEAI
treatment resulted in induction of several PPARd target genes
involved in the fatty acid oxidation pathway, uncoupling and
mitochondrial biogenesis including CPT1b, which cataliyzes the
esterification of acyl-CoA to form acyl-carnitine, the rate-limiting
step of fatty acid oxidation; PDK4, which plays an important role
in switching the fuel source from glucose to fatty acids by
inactivating pyruvate dehydrogenase; PGC1a, which is the key
mitochondrial transcription regulators; UCP3 which is involved in
energy expenditure; and LCAD, which is involved in mitochon-
drial fatty acid oxidation (Figure 3B). The upregulation of these
genes was completely abolished when PPARd expression was
knocked down (Figure 3B). Either WEAI or 50EEAI had no
detectable effects on induction of these PPARd target genes in the
same assay (data not shown). These results demonstrated that
activation of PPARd by a 95EEAI leads to elevated expression of
genes involved in lipid catabolism.
A 95EEAI promotes fatty acid oxidation and glucose
uptake
To determine whether 95EEAI has direct effects on fatty acid
oxidation and glucose uptake, we treated differentiated human
skeletal muscle cells with 95EEAI. Treatment of 95EEAI led to 2-
fold increase in fatty acid oxidation (p,0.05, Figure 4A). The
Figure 3. 95EEAI-induced effects on PPARd target gene expression in primary myotubes. Primary myotubes were transfected with PPARd
siRNA pool or control siRNA. At 48 h post-transfection, the cells were treated with 100 nM GW501516, 25 mg/ml 95EEAI or DMSO for 24 h. Cells were
harvested for real-time quantitative PCR (A, C) or western blotting (B) GAPDH RNA was used as an internal control for calculating mRNA fold changes.
Values are expressed mean 6 S.D. from three independent experiments. **, p,0.01; *, p,0.05 for DMSO controls; #,p ,0.05 for control siRNA versus
PPARd siRNA. One representative result is shown form three independent western blotting experiments.
doi:10.1371/journal.pone.0033815.g003
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prevented by the knockdown of PPARd (Figure 4A).
PPARd agonist GW501516 is known to enhance basal and
insulin-stimulated glucose uptake in human skeletal muscle [14].
As shown in Figure 4B, there was a 1.8-fold increase in insulin-
stimulated glucose uptake in 95EEAI-treated cells compared with
untreated control cells. However, in the absence of insulin
stimulation the increase in glucose uptake in 95EEAI treated cells
was not statistically significant. The siRNA-mediated reduction of
PPARd expression was without effect on the stimulation of glucose
uptake by either GW501516 or 95EEAI (Figure 4B).
A 95EEAI attenuates HFD-induced obesity in mice
We and others predicted that enhanced fatty acid utilization
and energy expenditure would protect against diet-induced obesity
[6]. To determine whether 95EEAI regulate the progression of
obesity, mice fed a HFD were orally administered the vehicle or
200 mg/kg 95EEAI once daily for 8 weeks. At the end of 8 weeks
high-fat diet feeding, male C57BL/6J mice showed a significant
increase in the rate of body weight gain compared with animals
fed a normal diet (terminal body weight: normal diet group,
26.361.8 g vs. HFD group, 37.662.1 g, p,0.01, n=9;
Figure 5A). In contrast, 95EEAI treatment of mice resulted in
significantly reduced body weight gain and fat pad mass compared
with the vehicle-treated mice on HFD (Figure 5A, B) without
reducing food consumption.
To verify whether 95EEAI stimulates fatty acid oxidation, we
measured the levels of fatty acid oxidation in quadriceps muscle.
95EEAI-treated mice on an HFD displayed higher levels of fatty acid
o x i d a t i o nt h a nt h a to fv e h i c l e - t r e a t e dm i c eo na nH F D( F i g u r e6 A ) .
Figure 4. Effects of 95EEAI on fatty acid oxidation and glucose uptake in primary myotubes. Primary myotubes were transfected with
PPARd siRNA or control siRNA. At 48 h post-transfection, the cells were with 100 nM GW501516, 25 mg/ml 95EEAI or DMSO for 24 h. (A) Cells were
changed to serum-free medium containing [
3H]palmitic acid.
3H2O production was assayed 4 h after incubation. (B) Cells were treated with or
without 100 nM insulin at 37uC for 10 min. Glucose uptake assays were conducted as described in Materials and Methods. The cpm results were
normalized with protein concentrations. Fold increases in insulin-stimulated glucose uptake were normalized to DMSO-treated control cells. Data
shown are means 6 S.D. and were obtained from six independent experiments carried out in triplicate. **, p,0.01; *, p,0.05 compared to DMSO
control; #,p ,0.05 for control siRNA versus PPARd siRNA.
doi:10.1371/journal.pone.0033815.g004
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oxidation in the skeletal muscle affected the levels of lipid-derived
substrates, such as nonesterified fatty acids (NEFAs), triglyceride
(TG), and ketone bodies in the circulation. The plasma levels of
free fatty acids and ketone bodies were significantly lower in
95EEAI-treated mice on an HFD than vehicle-treated mice on an
HFD (Table 1). However, there was no statistically significant
decrease in the plasma TG levels (Table 1).
To confirm that 95EEAI-induced fatty acid oxidation in skeletal
muscle in vivo was also associated with increased expression of
PPARd target genes involved in fatty acid oxidation pathway, we
analyzed the expression of some representative genes (CPT1,
LCAD, UCP2, UCP3, and PGC1a) by real-time quantitative
PCR assay. The levels of mRNA expression were determined in
individual animals, and the average expression for each group was
presented. Consistent with results from the primary human
myotubes, 95EEAI induced mRNA levels of these genes in
skeletal muscle (Figure 6B).
Discussion
Artemisia species are widely used in traditional medicine in East
Asia, and have been reported to show anti-obesity, anti-diabetic,
anti-lipogenic and anti-hyperglycaemic effects [15–20]. However,
the molecular mechanism involved in Artemisia-induced lipid/
carbohydrate metabolism is poorly understood. Since PPARd
activators have been shown to improve insulin resistance and
reduce plasma glucose in rodent models of type 2 diabetes and
reduce serum triglycerides in sedentary human [21,22], we aimed
to test whether AI extracts have the ability to activate PPARd as a
potential mechanism of action in mediating its beneficial effects.
We showed that 95EEAI interacted with the PPARd LBD
leading to its activation. A 95 EEAI increased the expression of
genes involved in lipid catabolism, enhanced fatty acid oxidation
and insulin-stimulated glucose uptake in vivo as well as in human
skeletal muscle cells, protected against diet-induced obesity.
Furthermore, in PPARd knockdown cells, the positive effects of
95EEAI on fatty acid oxidation and their related genes expression
Figure 5. A 95EEAI attenuates body weight gain and adiposity
in HFD-fed C57BL/6J mice. Male C57BL/6J mice were fed a normal
diet and vehicle, HDF and vehicle or HFD and 200 mg/kg/day 95EEAI for
8 weeks (A) Body weight change. (B) Adipose tissue weight. Values are
mean 6 S.D. of nine mice. #,p ,0.01 compared to normal diet/vehicle
group; **, p,0.01; *, p,0.05 compared to HFD/vehicle group.
doi:10.1371/journal.pone.0033815.g005
Figure 6. A 95EEAI increases skeletal muscle fatty acid
oxidation in C57BL/6J mice. Male C57BL/6J mice were fed a HDF
and vehicle or HFD and 200 mg/kg/day 95EEAI for 8 weeks (A) fatty acid
oxidation in skeletal muscle (B) Quantitative real-time PCR analysis in
skeletal muscle. Values are mean 6 S.D. of nine mice. ***, p,0.005; **,
p,0.01; *, p,0.05 compared to HFD/vehicle group.
doi:10.1371/journal.pone.0033815.g006
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metabolism would be PPARd-dependent. However, knockdown of
PPARd expression did not alter the 95EEAI-mediated increase in
insulin-stimulated glucose uptake. This result is in line with the
report by Kramer et al. suggesting that direct activation of PPARd
itself is not necessary for the stimulation of glucose uptake [23]. In
vivo study, administration of 95EEAI to mice fed a HFD had no
effect on fasting levels of blood glucose (Table 1). Our finding is in
line with the work of Tanka et al. [24] who was also unable to
detect changes in blood glucose levels in PPARd agonist-treated
mice, despite the marked improvement in glucose tolerance and
insulin sensitivity. Brunmair et al. [25] have reported that
activation of PPARd acts to suppress glucose utilization as a result
of a switch in substrate preference from carbohydrates to lipids in
skeletal muscle, thus PPARd agonist fails to exert any effect on
glucose uptake. Lee et al. [26] suggest that the improved glucose
tolerance and insulin sensitivity triggered by PPARd agonist is due
to promoting an increase in glucose flux through the pentose-
phosphate pathway and enhancing hepatic fatty acid synthesis.
More studies are needed to elucidate the exact relationship
between glucose utilization and 95EEAI-induced PPARd activa-
tion
During starvation, glucose uptake and oxidation are reduced
rapidly in muscle, which shifts to use free fatty acids and ketone
bodies. In this study, 95EEAI-treated mice on an HFD showed a
significant decrease in the plasma levels of free fatty acids and
ketone bodies (Table 1). Tanka et al. [24] showed that the changes
in gene expression by PPARd agonist are very similar to the gene
expression profile induced by fasting in skeletal muscle. Hence, we
speculate that the changes in levels of ketone bodies may be
attributed to, at least in part, an increased uptake of ketone bodies
in muscle through an activation of PPARd by 95EEAI.
The major compounds isolated from Artemisia species include
terpenoids, flavonoids, coumarins, acetylenes, caffeoylquinic acids,
and sterols [27] (Table S1). Major compounds of 95EEAI had no
detectable effect on activation of PPARd protein (data not shown).
Saturated and unsaturated fatty acids, such as arachidonic acid
and eicosapentaenoic acid, are reported to be natural ligands for
PPARd [28,29]. These fatty acids bind and activate PPARd in the
low micromolar range. Although the bioactive component from
95EEAI for activation of PPARd was not chemically characterized
yet, its structure may be similar to that of fatty acids.
Since activation of PPARd has shown to exert beneficial effects
on preventing obesity-related diseases [30], natural compounds
that enhance the activity of PPARd will provide a potential to
develop a functional food with anti-obesity and anti-diabetic
efficacies.
In summary, our data provide experimental evidence that
95EEAI is a natural PPARd agonist that robustly induces genes
involved in fatty acid metabolism and activates fatty acid oxidation
in vitro and in vivo, suggesting its potential as interventive and
preventive measures for the treatment of metabolic disorders.
Supporting Information
Figure S1 The effects of 95EEAI on PPARd target genes
expression in primary human myotubes. Primary human
myotubes were treated with different doses of 95EEAI (0, 10, 25,
100 mM) or DMSO for 24 h. Total RNA was extracted from cells,
and the mRNA levels of CPT1 and PDK4 genes were quantified
by a real-time RT-PCR. Data from 3 independent experiments
are represented as means 6 S.D. of the relative calculated with
GAPDH as standard. *, p,0.05; **, p,0.01 versus DMSO-treated
cells.
(TIF)
Table S1 Major chemical compounds in 95% ethanol
extracts of Artemisia iwayomogi tested identified by
GC-MS. The 95% ethanol extracts of Artemisia iwayomogi were
analyzed using the Thermo Scientific TRACE GC Ultra
TM gas
chromatograph. It was fitted with a split-splitless injector and
connected to an MS PolarisQ-Quadrupole Ion Trap (Thermo
Electron) fused silica column VB5 (5% phenyl, 95% methylpo-
lyxiloxane, 30 m with 0.25 mm i.d. film thickness 0.25 mm) (J &
W Scientific Fisons, Folsom, CA, USA). The injector and
interface were operated at 250 and 300uC, respectively. The
oven temperature was programmed as follows: 50uCr a i s e dt o
250uC( 4 uC/min) and held for 3 min. Helium was the carrier gas
at 1 ml/min. The sample (1 ml) was injected in the split mode
(1:20). MS conditions were as follows: ionization voltage EI of
70 eV, mass range 10–350 amu. The components were identi-
fied by comparing their relative retention times and mass spectra
with those of authentic samples (analytical standards from data
base).
(DOC)
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Table 1. Physical and metabolic parameters in 95EEAI- and
vehicle-treated mice.
Normal diet/
vehicle HFD/vehicle HFD/95EEAI
Body weight (g) 26.361.8 37. 662.2
# 31.360.76
*
Liver weight (g) 1.0860.1 1.0960.09 0.9860.04
Epidermal fat weight (g) 0.660.03 1.88.160.04
# 1.3760.07
**
Mesenteric fat weight (g) 0.2260.02 1.0360.06
# 0.7160.03
**
Food intake (g/day) 3.2560.8 2. 6860.9 2. 660.5
Glucose (mg/dl): fasted 110. 862.9 172.3615.2 186.611.1
TG (mmol/l) 0.6460.7 0.6160.4 0.5860.3
NEFA (mEq/l) 0.3160.01 0.5260.01
# 0. 3760.02
*
Ketone body (mmole/l) 200.3656.4 221.3630.1 121.2612.1
**
3-hydroxy-butylate
(mmole/l)
197.3634.2 191. 9628.7 130.2612.1
**
Total cholesterol (mmol/l) 2.0160.11 2.5160.09 2. 6360. 1
A 95EEAI (200 mg/kg) was orally administrated to mice once daily for 8 weeks.
Values are mean 6 S.D. of nine mice.
#,p ,0.01 compared to normal diet/vehicle group;
**, p,0.01;
*, p,0.05 compared to HFD/vehicle group.
doi:10.1371/journal.pone.0033815.t001
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